BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Follow-Up Questions
What is Bioatla Inc (BCAB)'s P/E Ratio?
The P/E ratio of Bioatla Inc is N/A
Who is the CEO of Bioatla Inc?
Dr. Jay Short is the Chairman of the Board of Bioatla Inc, joining the firm since 2007.
What is the price performance of BCAB stock?
The current price of BCAB is 0.6861, it has decreased 0.7% in the last trading day.
What are the primary business themes or industries for Bioatla Inc?
Bioatla Inc belongs to Biotechnology industry and the sector is Health Care
What is Bioatla Inc market cap?
Bioatla Inc's current market cap is $40.2
Is Bioatla Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Bioatla Inc, including 3 strong buy, 3 buy, 3 hold, 0 sell, and 3 strong sell
